Immunitybio announces results of phase 2 metastatic pancreatic cancer trial at asco gi with median overall survival of 6.3 months in patients with third-line disease, more than doubling historical survival

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced interim results (n=63) in its metastatic pancreatic cancer trial (quilt 88) showing that the overall survival rate for patients doubled compared to historical survival rate of three months after two prior lines of therapy (manax asco gi 2019). the data of the phase 2 trial studying a combination immunotherapy (nant cancer vaccine) also show treatment-related serious ad
IBRX Ratings Summary
IBRX Quant Ranking